Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 In addition, future studies should also be concentrated on selective inhibition of Akt1 and 2 isoforms, with experimental validation for the development of effective therapy against oral cancer.
Alan Kumar
 + 11619 word(s) 11619 2020-07-18 05:41:07 |
2 Format correct
Vicky Zhou
 -9978 word(s) 1641 2020-10-28 09:59:31 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Kumar, A. Akt in Oral Squamous. Encyclopedia. Available online: https://encyclopedia.pub/entry/1371 (accessed on 18 November 2024).
Kumar A. Akt in Oral Squamous. Encyclopedia. Available at: https://encyclopedia.pub/entry/1371. Accessed November 18, 2024.
Kumar, Alan. "Akt in Oral Squamous" Encyclopedia, https://encyclopedia.pub/entry/1371 (accessed November 18, 2024).
Kumar, A. (2020, July 18). Akt in Oral Squamous. In Encyclopedia. https://encyclopedia.pub/entry/1371
Kumar, Alan. "Akt in Oral Squamous." Encyclopedia. Web. 18 July, 2020.
Akt in Oral Squamous
Edit

Protein kinase B (Akt) plays a very significant role in various cancers including oral cancer. However, it has three isoforms (Akt1, Akt2, and Akt3) and they perform distinct functions and even play contrasting roles in different cancers. Therefore, it becomes essential to evaluate the isoform-specific role of Akt in oral cancer. In the present study, an attempt has been made to elucidate theisoform-specific role of Akt in oral cancer. The immunohistochemical analysis of oral cancer tissues showed an overexpression ofAkt1 and 2 isoforms but not Akt3. Moreover, the dataset of “The Cancer Genome Atlas” for head and neck cancer has suggested thegenetic alterations of Akt1 and 2 tend to be associated with the utmost poor clinical outcome in oral cancer. Further, treatment of oralcancer cells with tobacco and its components such as benzo(a)pyrene and nicotine caused increased mRNA levels of Akt1 and 2isoforms and also enhanced the aggressiveness of oral cancer cells in terms of proliferation, and clonogenic and migration potential.Finally, silencing of Akt1 and 2 isoforms caused decreased cell survival and induced cell cycle arrest at the G2/M phase. Akt1/2 silencing also reduced tobacco-induced aggressiveness by decreasing the clonogenic and migration potential of oral cancer cells.Moreover, silencing of Akt1 and 2 isoforms was found to decrease the expression of proteins regulating cancer cell survival andproliferation such as cyclooxygenase-2, B-cell lymphoma 2 (Bcl-2), cyclin D1, and survivin. Thus, the important role of Akt1 and 2isoforms have been elucidated in oral cancer with in-depth mechanistic analysis.

Akt isoforms oral cancer tissue microarray immunohistochemistry tobacco knockdown

1. Introduction

Oral cancer is one of the most challenging diseases faced by mankind, and regardless of several advances made in the field of oral cancerdiagnostics and therapeutics, it remains a global health concern.

It was responsible for approximately 145,400 deaths worldwide in the year 2012 [1]. Oral cancers are mostly carcinomas (96%), of which 91% aresquamous cell carcinomas. Variations in the incidence of this cancer are the result of several endogenous and exogenous factors such as tobacco use, alcohol intake, and human papilloma virus (HPV) infection. These factors result in numerous genetic and epigenetic changes that cause genomic instability and tumor development and progression [2][3][4][5][6][7]. The overall and disease-free survival rates of oral squamous cell carcinoma (OSCC) patients remain unchanged due to high mortality and low cure rate. This is mainly due to the lack of proper diagnostic and therapeutic biomarkers forbetter diagnosis and prognosis and the lack of effective therapies [8][9][10]. Therefore, it becomes imperative to focus on those molecular mediators that play a key role in oral cancer development and progression.

Several decades of research have established that the protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway is highly upregulated in oral cancer and leads to its development. The aforementioned risk factors for oral cancer such as tobacco, alcohol, and HPV werealso found to induce activation of the Akt/mTOR pathway [11][12][13]. This pathway is a network of many proteins that interact and induce different cellular processes such as cancer cell survival, proliferation, invasion, angiogenesis, and tumor metastasis. Akt kinase is the key protein of thispathway and its activation is responsible for inducing tumorigenesis by affecting different hallmarks of cancer [14][15][16][17][18][19][20][21][22][23][24][25][26].

Multiple lines of evidence suggest that Akt isoforms are involved in the development of different cancers such as ovarian, colorectal, pancreatic, breast, and lung cancer [27][28][29][30][31]. However, it is well-known that Akt kinase exists in three different isoforms as Akt1, Akt2, and Akt3, and these display distinct functions in various cancers [32]. Additionally, the precise role of Akt isoforms in the development of oral cancer has not been studied thoroughly. Therefore, the present study intended to evaluate the role of different Akt isoforms in the pathogenesis of oral cancer.Moreover, an attempt was made to analyze their association with tobacco, the main risk factor for oral cancer. Deciphering the molecular network ofAkt isoforms in the development of OSCC can provide a specific target against which appropriate therapeutic modalities can be developed for effective prevention and treatment of this disease.

2.  The Role of Different Akt Isoforms in the Development of Oral Cancer

Analysis of the differential expression of Akt isoforms in oralcancer tissues showed overexpression of Akt1 and 2 isoforms. Additionally, the expression of Akt1 and 2 isoforms varied with the different stages of cancer and it gradually increased with advanced stages of oral cancer. A previous report by Iamaroon and Krisanaprakornkit has also shown theoverexpression of Akt1 and 2 in OSCC [33]. Moreover, the overexpression of Akt1 and 2 isoforms have been reported in many other cancers such as breast, liver, lung, glioma, and neuroblastoma [32].Differential expression of Akt isoforms was also observed in several tumor tissue types, and previous studies have suggested the important role ofAkt isoforms in inflammatory conditions, especially in vascular diseases [34][35]. However, no such study of Akt isoform-specific involvement in other tissue types has been reported. In line with our observations, the expression of Akt1 and 2 were found to be different in early and late stages ofbreast cancer [36].

Our study has shown the overexpression of Akt1 and 2 isoforms in different regions of the oral cavity such as the tongue, cheek, and gingiva.A couple of studies have shown the activation of Akt in tongue cancer is associated with adverse outcomes [37][38]. Thus, it might be possible that out of all three isoforms, only Akt1 and 2 play a key role in tongue cancer development. On exploring the TCGA dataset, it was observed that all three Akt kinase isoforms have a considerable percentage of genetic alterations in HNSCC, but in our study, the IHC analysis of oral cancer tissues showedhigh expression of Akt1 and 2 isoforms but not Akt3 compared to the normal tissues. The HNSCC includes different types of cancer including OSCC. OSCC is more confined to the oral cavity region, which is different from the other section of the head and neck region such as oropharynx andlarynx. The other regions of the head and neck are different from the oral cavity region both physiologically and histologically and this differencemight be responsible for a discrepancy in the association of Akt isoforms. The disparity in the association of Akt isoforms is not only limited to HNSCC and OSCC but prevalent in other cancers as well. Regardless of the discrepancy in the association of the Akt isoforms in HNSCC and OSCC, only the genetic alteration associated with Akt1 and 2 isoforms were associated with poor OS and genetic alteration of Akt2 isoform was linked with poor DFS of HNSCC patients. Consistent with our observations, previous reports have also implied the profound significance of Akt1 and 2 gene expression in the prognosis of different cancers such as esophageal squamous cell carcinoma and non-small cell lung carcinoma [32][39][40][41][42][43]. Therefore, it becomes evident that both Akt1 and 2 might play a significant role in clinical outcomes of oral cancer patients. Therefore, a detailed mechanistic interpretation can help in deciphering the distinct role of Akt isoforms in oral cancer development, thereby allowing effective therapeutics to be developed.

It is well recognized that tobacco is a prime risk factor for oral cancer, and our results have shown increased cell proliferation of oral cancer cells following treatment with tobacco and its components. In line with our results, previous studies have also suggested the increased proliferation of cancer cells on exposure to tobacco [44][45]. Moreover, many studies have suggested that treatment with the tobacco component BAP canincrease the proliferation of normal cells and cancer cells such as ovarian, breast, lung, and gastric cancer cells [46][47][48][49]. Nicotine is an importantcomponent of tobacco and it has long been associated with several cancers such as cancers of lung, head and neck, gastric, pancreatic, gallbladder,liver, colon, breast, cervical, urinary bladder, and kidney [50].

In our analysis, we found that the silencing of Akt1 and 2 isoforms caused an increase in the percentage of cell death in oral cancer cells. Likewise, previous studies have also suggested the importance of Akt1 and 2 in cell survival and indicated that these isoforms mediate the process ofcell survival through different routes [51][52][53]. Similar to our results, in other cancers such as breast, lung, and colorectal cancers, the important role of Akt1 and 2 isoforms have been shown in the process of cell survival through induction of apoptosis [36][51][54]. Finally, we observed that silencingof Akt2 led to the decreased expression of proteins such as Cox-2, Cyclin D1, Bcl-2, and survivin, while silencing of Akt1 only led to a reduction in Cox-2 levels. Cox-2 and serine threonine kinase Akt signaling pathway possess a strong correlation [55]. For instance, in the case of endometrial cancer,Akt was found to regulate the expression of Cox-2 at both gene and protein level in phospho-Akt expressing cells [56]. Further, in epithelial ovariancancer, overexpression of COX-2 was reported to be strongly associated with Akt activation, suggesting the correlation between Cox-2 and Akt [57].

3. Conclusions

The current study aimed at evaluating the expression and delineating the role of different Akt isoforms in the development of oral cancer. Ourresults suggest the overexpression of Akt1 and 2 with respect to migration and expression of Bcl-2, cyclin D1, and survivin proteins, which areimportant for cancer cell survival and proliferation. However, our study has not elucidated the detailed role of the Akt3 isoform, which might playan important role in HNSCC and hence should be studied in the near future. Therefore, general targeting of the total Akt kinases would not be effective in the prevention and treatment of oral cancer. Specific targeting of the Akt1 and 2 isoforms would result in a better prognosis for oralcancer patients. Moreover, our results also indicated a strong association of Akt1/2 isoforms with tobacco (one of the major risk factors of oral cancer) induced cancer cell viability and migration, which can be further studied to explore the other molecular mediators linked with Akt isoforms and tobacco mediated oral carcinogenesis, and to establish a signaling axis that regulates this process. In addition, future studies should also be concentrated on selective inhibition of Akt1 and 2 isoforms, with experimental validation for the development of effective therapy against oralcancer.

References

  1. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108.
  2. Silverman, S.; Gorsky, M. Epidemiologic and Demographic Update in Oral Cancer: California and National Data—1973 to 1985. J. Am. Dent. Assoc. 1990, 120, 495–499.
  3. Blot, W.J.; McLaughlin, J.K.; Winn, D.M.; Austin, D.F.; Greenberg, R.S.; Preston-Martin, S.; Bernstein, L.; Schoenberg, J.B.; Stemhagen, A.; Fraumeni, J.F. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988, 48, 3282–3287.
  4. De Stefani, E.; Victora, C.G.; Castelletto, R.; Castellsagué, X.; Muñoz, N.; Rolón, P.A.; Quintana, M.J. Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int. J. Cancer 1999, 82, 657–664.
  5. Schlecht, N.F. Prognostic value of human papillomavirus in the survival of head and neck cancer patients: An overview of the evidence. Oncol. Rep. 2005, 14, 1239–1247.
  6. Fakhry, C.; Westra, W.H.; Li, S.; Cmelak, A.; Ridge, J.A.; Pinto, H.; Forastiere, A.; Gillison, M.L. Improved Survival of Patients with Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial. J. Natl. Cancer Inst. 2008, 100, 261–269.
  7. Manoharan, N.; Tyagi, B.B.; Raina, V. Cancer incidences in rural Delhi—2004–05. Asian Pac. J. Cancer Prev. 2010, 11, 73–77.
  8. Bell, R.B.; Kademani, D.; Homer, L.; Dierks, E.J.; Potter, B.E. Tongue Cancer: Is There a Difference in Survival Compared With Other Subsites in the Oral Cavity? J. Oral Maxillofac. Surg. 2007, 65, 229–236.
  9. Massano, J.; Regateiro, F.S.; Januário, G.; Ferreira, A. Oral squamous cell carcinoma: Review of prognostic and predictive factors. Oral Surgery Oral Med. Oral Pathol. Oral Radiol. Endodontol. 2006, 102, 67–76.
  10. Mydlarz, W.K.; Hennessey, P.T.; Califano, J.A. Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer. Expert Opin. Med. Diagn. 2010, 4, 53–65.
  11. West, K.A.; Clark, A.S.; Linnoila, I.R.; Yang, X.; Harris, C.; Belinsky, S.; Dennis, P.A.; Brognard, J.; Swain, S.M. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J. Clin. Investig. 2003, 111, 81–90.
  12. Neasta, J.; Ben Hamida, S.; Yowell, Q.V.; Carnicella, S.; Ron, D. AKT Signaling Pathway in the Nucleus Accumbens Mediates Excessive Alcohol Drinking Behaviors. Boil. Psychiatry 2011, 70, 575–582.
  13. Surviladze, Z.; Sterk, R.T.; DeHaro, S.A.; Ozbun., M.A. Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy. J. Virol. 2013, 87, 2508–2517.
  14. Bellacosa, A.; Kumar, C.C.; Di Cristofano, A.; Testa, J.R. Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting. Advan. Cancer Res. 2005, 94, 29–86.
  15. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489–501.
  16. Baek, S.H.; Ko, J.H.; Lee, J.H.; Kim, C.; Lee, H.; Nam, D.; Lee, J.; Lee, S.G.; Yang, W.M.; Um, J.Y.; et al. Ginkgolic Acid Inhibits Invasion and Migration and TGF-β-Induced EMT of Lung Cancer Cells Through PI3K/Akt/mTOR Inactivation. J. Cell. Physiol. 2017, 232, 346–354.
  17. Mohan, C.D.; Srinivasa, V.; Rangappa, S.; Mervin, L.; Mohan, S.; Paricharak, S.; Baday, S.; Li, F.; Shanmugam, M.K.; Chinnathambi, A.; et al. Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway. PLoS ONE 2016, 11, e0153155.
  18. Singh, S.S.; Yap, W.N.; Arfuso, F.; Kar, S.; Wang, C.; Cai, W.; Dharmarajan, A.M.; Sethi, G.; Kumar, A.P. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine? World J. Gastroenterol. 2015, 21, 12261–12273.
  19. Siveen, K.S.; Ahn, K.S.; Ong, T.H.; Shanmugam, M.K.; Li, F.; Yap, W.N.; Kumar, A.P.; Fong, C.W.; Tergaonkar, V.; Hui, K.M.; et al. γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model. Oncotarget 2014, 5, 1897–1911.
  20. Kim, S.W.; Kim, S.M.; Bae, H.; Nam, D.; Lee, J.H.; Lee, S.G.; Shim, B.S.; Kim, S.H.; Ahn, K.S.; Choi, S.H.; et al. Embelin inhibits growth and induces apoptosis through the suppression of Akt/mTOR/S6K1 signaling cascades. Prostate 2013, 73, 296–305.
  21. Park, K.-R.; Nam, D.; Yun, H.-M.; Lee, S.-G.; Jang, H.-J.; Sethi, G.; Cho, S.K.; Ahn, K.S. β-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation. Cancer Lett. 2011, 312, 178–188.
  22. Lee, J.H.; Kim, C.; Lee, S.-G.; Yang, W.M.; Um, J.-Y.; Sethi, G.; Ahn, K.S. Ophiopogonin D modulates multiple oncogenic signaling pathways, leading to suppression of proliferation and chemosensitization of human lung cancer cells. Phytomedicine 2018, 40, 165–175.
  23. Ko, J.-H.; Nam, D.; Um, J.-Y.; Jung, S.H.; Sethi, G.; Ahn, K.S. Bergamottin Suppresses Metastasis of Lung Cancer Cells through Abrogation of Diverse Oncogenic Signaling Cascades and Epithelial-to-Mesenchymal Transition. Molecules 2018, 23, 1601.
  24. Lee, H.; Baek, S.H.; Lee, J.H.; Kim, C.; Ko, J.H.; Lee, S.G.; Chinnathambi, A.; Alharbi, S.A.; Yang, W.M.; Um, J.Y.; et al. Isorhynchophylline, a Potent Plant Alkaloid, Induces Apoptotic and Anti-Metastatic Effects in Human Hepatocellular Carcinoma Cells through the Modulation of Diverse Cell Signaling Cascades. Int. J. Mol. Sci. 2017, 18, 1095.
  25. Kannaiyan, R.; Manu, K.A.; Chen, L.; Li, F.; Rajendran, P.; Subramaniam, A.; Lam, P.; Kumar, A.P.; Sethi, G. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis 2011, 16, 1028–1041.
  26. Sethi, G.; Ahn, K.S.; Sung, B.; Kunnumakkara, A.B.; Chaturvedi, M.M.; Aggarwal, B.B. SH-5, an AKT inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by IκBα kinase activation. Biochem. Pharmacol. 2008, 76, 1404–1416.
  27. Lorenzato, A.; Biolatti, M.; Delogu, G.; Capobianco, G.; Farace, C.; Dessole, S.; Cossu, A.G.M.; Tanda, F.; Madeddu, R.; Olivero, M.; et al. AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells. Exp. Cell Res. 2013, 319, 2627–2636.
  28. Rychahou, P.G.; Kang, J.; Gulhati, P.; Doan, H.Q.; Chen, L.A.; Xiao, S.-Y.; Chung, D.H.; Evers, B.M. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc. Natl. Acad. Sci. USA 2008, 105, 20315–20320.
  29. Cheng, J.Q.; Ruggeri, B.; Klein, W.M.; Sonoda, G.; Altomare, D.A.; Watson, D.K.; Testa, J.R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA 1996, 93, 3636–3641.
  30. Iacovides, D.C.; Johnson, A.B.; Wang, N.; Boddapati, S.; Korkola, J.; Gray, J.W. Identification and Quantification of AKT Isoforms and Phosphoforms in Breast Cancer Using a Novel Nanofluidic Immunoassay. Mol. Cell. Proteom. 2013, 12, 3210–3220.
  31. Qiu, Z.-X.; Zhang, K.; Qiu, X.-S.; Zhou, M.; Li, W.-M. The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS ONE 2013, 8, e81451.
  32. Roy, N.; Golla, R.; Kunnumakkara, A.; Kotoky, J. Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer. Curr. Drug Targets 2017, 18, 421–435.
  33. Iamaroon, A.; Krisanaprakornkit, S. Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncol. 2009, 45, e175–e179.
  34. Di Lorenzo, A.; Fernandez-Hernando, C.; Cirino, G.; Sessa, W.C. Akt1 is critical for acute inflammation and histamine-mediated vascular leakage. Proc. Natl. Acad. Sci. USA 2009, 106, 14552–14557.
  35. Yu, H.; Littlewood, T.; Bennett, M. Akt isoforms in vascular disease. Vasc. Pharmacol. 2015, 71, 57–64.
  36. Riggio, M.; Perrone, M.C.; Polo, M.L.; Rodriguez, M.J.; May, M.; Abba, M.; Lanari, C.; Novaro, V. AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. Sci. Rep. 2017, 7, 44244.
  37. Watanabe, S.; Sato, K.; Okazaki, Y.; Tonogi, M.; Tanaka, Y.; Yamane, G.-Y. Activation of PI3K-AKT Pathway in Oral Epithelial Dysplasia and Early Cancer of Tongue. Bull. Tokyo Dent. Coll. 2009, 50, 125–133.
  38. Massarelli, E.; Liu, D.D.; Lee, J.J.; El-Naggar, A.K.; Muzio, L.L.; Staibano, S.; De Placido, S.; Myers, J.N.; Papadimitrakopoulou, V.A. Akt activation correlates with adverse outcome in tongue cancer. Cancer 2005, 104, 2430–2436.
  39. Tumino, R.; Vicario, G. Head and neck cancers: Oral cavity, pharynx, and larynx. Epidemiol. Prev. 2004, 28, 28–33.
  40. Roy, N.K.; Bordoloi, D.; Monisha, J.; Singh, A.; Padmavathi, G.; Kunnumakkara, A.B. Isoform-specific Role of Akt Kinase in Cancer and its Selective Targeting by Potential Anticancer Natural Agents. Nat. Prod. J. 2017. Ahead of print.
  41. Zhu, Z.; Yu, W.; Fu, X.; Sun, M.; Wei, Q.; Li, D.; Chen, H.; Xiang, J.; Li, H.; Zhang, Y.; et al. Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma. J. Exp. Clin. Cancer Res. 2015, 34, 2893.
  42. Yu, W.; Chu, L.; Zhao, K.; Chen, H.; Xiang, J.; Zhang, Y.; Li, H.; Zhao, W.; Sun, M.; Wei, Q.; et al. A nomogram based on phosphorylated AKT1 for predicting locoregional recurrence in patients with oesophageal squamous cell carcinoma. J. Cancer 2017, 8, 3755–3763.
  43. Miao, X.; Song, Y.; Lv, T.; Zhan, P.; Lv, Y.; Yuan, D. Expression and prognostic value of AKT2 in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2011, 14, 396–399.
  44. Tsurutani, J.; Castillo, S.; Brognard, J.; Granville, C.A.; Zhang, C.; Gills, J.J.; Sayyah, J.; Dennis, P.A. Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells. Carcinogenesis 2005, 26, 1182–1195.
  45. Sobus, S.L.; Warren, G.W. The biologic effects of cigarette smoke on cancer cells. Cancer 2014, 120, 3617–3626.
  46. Stopper, H.; Schmitt, E.; Gregor, C.; Mueller, S.O.; Fischer, W.H. Increased cell proliferation is associated with genomic instability: Elevated micronuclei frequencies in estradiol-treated human ovarian cancer cells. Mutagenesis 2003, 18, 243–247.
  47. Burdick, A.D.; Davis, J.W.; Liu, K.J.; Hudson, L.G.; Shi, H.; Monske, M.L.; Burchiel, S.W. Benzo(a)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells. Cancer Res. 2003, 63, 7825–7833.
  48. Kometani, T.; Yoshino, I.; Miura, N.; Okazaki, H.; Ohba, T.; Takenaka, T.; Shoji, F.; Yano, T.; Maehara, Y. Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway. Cancer Lett. 2009, 278, 27–33.
  49. Wei, Y.; Zhao, L.; Chen, Y.; He, W.; Yang, J.; Geng, C.; Liu, T.; Chen, H.; Li, Y. Benzo[a]pyrene promotes gastric cancer cell proliferation and metastasis likely through the Aryl hydrocarbon receptor and ERK-dependent induction of MMP9 and c-myc. Int. J. Oncol. 2016, 49, 2055–2063.
  50. Grando, S.A. Connections of nicotine to cancer. Nat. Rev. Cancer 2014, 14, 419–429.
  51. Lee, M.W.; Kim, D.S.; Lee, J.H.; Lee, B.S.; Lee, S.H.; Jung, H.L.; Sung, K.W.; Kim, H.T.; Yoo, K.H.; Koo, H.H. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Sci. 2011, 102, 1822–1828.
  52. Sugatani, T.; Hruska, K.A. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J. Biol. Chem. 2005, 280, 3583–3589.
  53. Calamito, M.; Juntilla, M.M.; Thomas, M.; Northrup, D.L.; Rathmell, J.; Birnbaum, M.J.; Koretzky, G.; Allman, D. Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood 2010, 115, 4043–4050.
  54. Haggblad Sahlberg, S.; Mortensen, A.C.; Haglof, J.; Engskog, M.K.; Arvidsson, T.; Pettersson, C.; Glimelius, B.; Stenerlow, B.; Nestor, M. Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells. Int. J. Oncol. 2017, 50, 5–14.
  55. Gately, S. The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis. Cancer Metastasis Rev. 2000, 19, 19–27.
  56. St-Germain, M.-È; Gagnon, V.; Parent, S.; Asselin, E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-κB/IκB pathway. Mol. Cancer 2004, 3, 7.
  57. Uddin, S.; Ahmed, M.; Hussain, A.; Assad, L.; Bavi, P.; Munkarah, A.; Al-Dayel, F.; Al-Kuraya, K.S.; Al-Dayel, F.; Al-Kuraya, K.S. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int. J. Cancer 2010, 126, 382–394.
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Alan Kumar
View Times: 720
Revisions: 2 times (View History)
Update Date: 28 Oct 2020
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback